金融界2025年8月24日消息，富国精准医疗混合A(005176) 最新净值3.6775元，该基金近一周收益 率-0.27%，近3个月收益率26.29%，今年来收益率65.04%。 该基金股票持仓前十分别为：惠泰医疗、海思科、百利天恒、科伦药业、泽璟制药-U、诺诚健华-U、 信立泰、澳华内镜、百济神州-U、悦康药业。前十持仓占比合计70.14%。 来源：金融界 富国精准医疗混合A基金成立于2017年11月16日，基金经理赵伟，截至2025年6月30日，富国精准医疗 混合A规模36.45亿元。 ...

该基金股票持仓前十分别为：惠泰医疗、海思科、百利天恒、科伦药业、泽璟制药-U、诺诚健华-U、 信立泰、澳华内镜、百济神州-U、悦康药业。前十持仓占比合计70.14%。 来源：金融界 金融界2025年8月17日消息，富国精准医疗混合A(005176) 最新净值3.6874元，该基金近一周收益率 2.37%，近3个月收益率37.35%，今年来收益率65.48%。 富国精准医疗混合A基金成立于2017年11月16日，基金经理赵伟，截至2025年6月30日，富国精准医疗 混合A规模36.45亿元。 ...

Group 1 - The core viewpoint of the article highlights the performance and holdings of the Fuqua Precision Medicine Mixed A Fund, which has shown significant returns in recent periods [1] - As of August 10, 2025, the latest net value of the fund is 3.6019 yuan, with a weekly return of -0.82%, a three-month return of 32.01%, and a year-to-date return of 61.64% [1] - The fund was established on November 16, 2017, and as of June 30, 2025, it has a total scale of 3.645 billion yuan [1] Group 2 - The top ten stock holdings of the fund include Huatai Medical, Haishi Ke, Baile Tianheng, Kelun Pharmaceutical, Zexing Pharmaceutical-U, Nuocheng Jianhua-U, Xinlitai, Aohua Endoscopy, Baijie Shenzhou-U, and Yuekang Pharmaceutical, with a combined holding percentage of 70.14% [1]

Group 1 - The core point of the article highlights the performance and holdings of the Fuqua Precision Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of June 30, 2025, the fund's total assets amount to 3.645 billion yuan, with a recent net value of 3.5414 yuan, reflecting a decrease of 0.52% [1] - The fund's performance over the past month, six months, and year-to-date shows returns of 13.75%, 60.55%, and 58.93% respectively, ranking 114 out of 1894, 12 out of 1876, and 8 out of 1866 in its category [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A fund account for a total of 70.14%, with notable positions in companies such as Huatai Medical (9.23%) and Haisco (8.62%) [1] - The fund was established on November 16, 2017, and is managed by Zhao Wei, who has extensive experience in the pharmaceutical and investment sectors [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Fuqua Precision Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of July 16, 2025, the latest net value of the fund is 3.3753 yuan, with a growth of 0.57% [1] - The fund's one-month return is 2.71%, ranking 1538 out of 2330 in its category; the six-month return is 56.76%, ranking 7 out of 2305; and the year-to-date return is 51.47%, ranking 11 out of 2296 [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A fund account for a total of 69.71%, with the largest holdings being Baili Tianheng (9.66%), Haizike (9.65%), and Kelun Pharmaceutical (9.10%) [1] - The fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager is Zhao Wei, who has extensive experience in the pharmaceutical and investment sectors [2]

Core Viewpoint - The recent resignation of star fund manager Yu Yang from two funds managed by Wutong Fund has sparked significant industry attention, raising concerns about the career paths of star fund managers, talent mobility in the public fund industry, and performance pressures [1][6]. Group 1: Manager Resignation - Yu Yang's resignation was anticipated, as he had been gradually stepping back from managing his funds since March, with co-managers being appointed to both funds prior to his departure [2][6]. - After his resignation, the management of the funds will be taken over by Lin Qing and Zhang Hong, respectively [2]. Group 2: Career Background - Yu Yang began his career in 2011, combining academic and practical experience, with a strong background in pharmaceutical investment [3]. - He joined Wutong Fund in 2015 and achieved remarkable returns, including a 138.63% return on the Wutong New Power Flexible Allocation Mixed Fund during his initial management period [3][4]. Group 3: Performance Issues - Following his return to Wutong Fund in December 2021, Yu Yang's performance did not meet market expectations, with a cumulative loss of 11.29% during his management of the Wutong New Power fund [5]. - The management scale of his funds significantly decreased, from 76.60 billion yuan to 40.74 billion yuan, indicating a near halving of assets under management [5]. Group 4: Industry Trends - Yu Yang's departure reflects a broader trend in the public fund industry, where the number of fund manager resignations has increased, indicating deeper changes within the industry [7]. - The industry is moving away from reliance on star fund managers towards a more team-based and platform-oriented investment research system, as emphasized by regulatory guidance [7][8].

Group 1 - The core point of the article highlights the performance and holdings of the Fuqua Precision Medical Mixed A fund, which has shown significant returns over various time frames [1] - As of June 20, 2025, the latest net value of the fund is 3.0382 yuan, reflecting a decrease of 0.86% [1] - The fund's one-month return is 7.22%, ranking 29 out of 1536 in its category; the six-month return is 32.59%, ranking 7 out of 1518; and the year-to-date return is 36.35%, ranking 8 out of 1519 [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A fund account for a total of 69.71%, with significant positions in companies such as Baile Tianheng (9.66%), Haizike (9.65%), and Kelun Pharmaceutical (9.10%) [1] - The fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager, Zhao Wei, has extensive experience in the pharmaceutical and investment sectors, having held various positions in notable companies before joining Fuqua [2]

Core Viewpoint - The report highlights the performance and holdings of the Fuqua Precision Medical Mixed A Fund, showcasing its strong returns and key stock positions in the healthcare sector [1]. Fund Performance - The latest net value of Fuqua Precision Medical Mixed A is 3.2727 yuan, with a growth of 0.62% - The fund's one-month return is 18.98%, ranking 20 out of 2331 in its category - Over the past six months, the return is 35.63%, ranking 14 out of 2295 - Year-to-date, the return stands at 46.87%, ranking 12 out of 2306 [1]. Fund Holdings - The top ten stock holdings of Fuqua Precision Medical Mixed A account for a total of 69.71%, with the following key positions: - Baillie Gifford (9.66%) - Haisco (9.65%) - Kelun Pharmaceutical (9.10%) - Huatai Medical (9.05%) - Zai Lab (7.84%) - Hansoh Pharmaceutical (5.95%) - Innovent Biologics (5.29%) - Sinovac Biotech (5.11%) - BeiGene (4.91%) - Zhaoke Pharmaceutical (3.15%) [1]. Fund Manager Background - Zhao Wei, the fund manager, has a master's degree and extensive experience in the pharmaceutical and investment sectors - Previous roles include positions at GlaxoSmithKline, GF Securities, and China Merchants Fund Management - Zhao has managed various funds focused on healthcare and small-cap investments before joining Fuqua Fund Management in March 2021 [2].

Group 1 - The core viewpoint of the news is the performance and holdings of the Fuqua Precision Medical Mixed A Fund, which has shown significant growth in recent months and year-to-date [1] - As of June 4, 2025, the latest net value of the fund is 3.1336 yuan, reflecting a growth of 1.37% [1] - The fund's one-month return is 9.95%, ranking 66 out of 2330 in its category, while its three-month return is 30.39%, ranking 10 out of 2320 [1] - Year-to-date, the fund has achieved a return of 40.63%, ranking 12 out of 2307 [1] Group 2 - The top ten stock holdings of the Fuqua Precision Medical Mixed A Fund account for a total of 69.71%, with significant positions in companies such as Baile Tianheng (9.66%), Haizike (9.65%), and Kelun Pharmaceutical (9.10%) [1] - The fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager, Zhao Wei, has extensive experience in the pharmaceutical and investment sectors, having held various positions in companies such as GlaxoSmithKline and China Merchants Fund Management [2]

Group 1 - The core point of the article highlights the performance and holdings of the Fuqua Precision Medical Mixed A fund, which has shown a recent decline in net value but strong returns over various time frames [1] - As of May 26, 2025, the latest net value of the fund is 2.8398 yuan, reflecting a decrease of 1.76%. The fund's one-month return is 1.98%, six-month return is 20.94%, and year-to-date return is 27.44% [1] - The fund's top ten stock holdings account for a total of 69.71%, with significant positions in companies such as Baillie Gifford (9.66%), Haisco (9.65%), and Kelun Pharmaceutical (9.10%) [1] Group 2 - The Fuqua Precision Medical Mixed A fund was established on November 16, 2017, and as of March 31, 2025, it has a total scale of 3.746 billion yuan [1] - The fund manager, Zhao Wei, has extensive experience in the pharmaceutical and investment sectors, having held various positions in companies such as GlaxoSmithKline and China Merchants Fund Management [2]